Awakn Life Sciences Corp.
AWKN
CNSX
| 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -4.51% | 34.35% | 41.95% | -45.13% | 65.47% |
| Total Depreciation and Amortization | -2.94% | -2.86% | 0.00% | -23.91% | 70.37% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -18.03% | -10.29% | -72.05% | 31.49% | 103.33% |
| Change in Net Operating Assets | -176.96% | 16,921.43% | -99.73% | 713.64% | -123.35% |
| Cash from Operations | -17,528.00% | 100.68% | -401.90% | 84.74% | 85.10% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -100.00% |
| Other Investing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Investing | -- | -- | -- | -- | -100.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -33.61% | 201.94% | -- | -- | -9.31% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Financing | -33.43% | 199.31% | 690.98% | -104.33% | -0.51% |
| Foreign Exchange rate Adjustments | -82.35% | -112.14% | 226.13% | -200.00% | -94.95% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -135.05% | 304.69% | -93.58% | -218.59% | 103.81% |